Abstract
Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 333-350 |
| Number of pages | 18 |
| Journal | Medical Clinics of North America |
| Volume | 101 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2017 |
Fingerprint
Keywords
- Anemia
- Azacitidine
- Blood and marrow transplant
- Myelodysplastic syndrome
- Therapy-related myelodysplastic syndrome
ASJC Scopus subject areas
- Medicine(all)
Cite this
Myelodysplastic Syndromes : Updates and Nuances. / Dao, Kim-Hien.
In: Medical Clinics of North America, Vol. 101, No. 2, 01.03.2017, p. 333-350.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Myelodysplastic Syndromes
T2 - Updates and Nuances
AU - Dao, Kim-Hien
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.
AB - Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.
KW - Anemia
KW - Azacitidine
KW - Blood and marrow transplant
KW - Myelodysplastic syndrome
KW - Therapy-related myelodysplastic syndrome
UR - http://www.scopus.com/inward/record.url?scp=85012206664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012206664&partnerID=8YFLogxK
U2 - 10.1016/j.mcna.2016.09.006
DO - 10.1016/j.mcna.2016.09.006
M3 - Review article
C2 - 28189174
AN - SCOPUS:85012206664
VL - 101
SP - 333
EP - 350
JO - Medical Clinics of North America
JF - Medical Clinics of North America
SN - 0025-7125
IS - 2
ER -